PSA Test Kit

Immunoassay for prostate-specific antigen measurement in prostate cancer screening. Provides quantitative measurement for clinical decision-making.

FIA-based quantitative test kit for PSA measurement in prostate health screening. Designed for point-of-care testing applications.

Rapid home test kit for semi-quantitative detection of prostate-specific antigen in human whole blood. Enables self-screening for prostate health status with results available within 15 minutes. ISO 13485:2016 certified for accuracy and reliability.

An enzyme-linked immunosorbent assay (ELISA) kit for the quantitative measurement of total prostate specific antigen in human serum samples. The assay has an assay time of 105 minutes, a shelf stability of 12 months, and a sensitivity of 0.1 ng/mL. Reference: CAN-TPSA-4300.

Chemiluminescence immunoassay for total prostate-specific antigen measurement with analytical sensitivity of 0.005 ng/ml and linearity up to 100 ng/ml.

A lateral flow immunoassay test kit for detection of prostate-specific antigen levels. This test aids in prostate health screening and early detection of abnormalities.

Immunofluorescence test kit for simultaneous detection of AFP, CEA, and total PSA biomarkers. Used for cancer screening and monitoring in clinical laboratories and point-of-care settings. Provides rapid quantitative results for liver, colorectal, and prostate cancer assessment.

An enzyme-linked immunosorbent assay (ELISA) kit for the quantitative measurement of free prostate specific antigen in human serum samples. The assay has an assay time of 75 minutes, a shelf stability of 18 months, and a sensitivity of 0.05 ng/mL. Reference: CAN-FPSA-4400.

A non-invasive, urine-sample-based diagnostic kit for prostate cancer detection and risk assessment. The kit utilizes PSA N-glycosylation analysis to detect asparagine-linked carbohydrates of PSA, providing comprehensive clinical insights into prostate cancer-related alterations. It employs recombinant antibody technology to ensure selectivity and cost-effectiveness, and is designed for simplicity, requiring no specialized or highly skilled operator personnel. The diagnostic method significantly reduces false-positive rates compared to conventional serum PSA tests.

Non-invasive urine-based diagnostic test that analyzes asparagine-linked carbohydrates of PSA to detect prostate cancer and assess disease aggressiveness. The assay provides comprehensive N-glycomic profiling in a single test, reducing false positives and unnecessary clinical interventions.

Rapid screening assays for AFP, CEA, PSA, and other key oncology markers enabling accessible, early-stage risk stratification in community health screening and specialist oncology settings. Offers quantitative fluorescence and semi-quantitative formats with low sample volume requirements of 50–100 µL serum/plasma. Multi-marker combo panels are available.

Rapid immunochromatographic test kit for simultaneous detection of HIV 1/2 antibodies and PSA antigen in whole blood, serum, or plasma. Delivers results within 10-15 minutes, enabling point-of-care screening in clinical and field settings. Single-use cassette format with high sensitivity and specificity for reliable diagnostic outcomes.